OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
May 28, 2020
CordenPharma and Moderna extended a strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna’s vaccine against SARS-CoV-2.
Advent manufactured the vaccine doses for the Phase 2/3 clinical trial.
May 27, 2020
A network-based supply chain approach has the potential to improve resilience and performance.
May 26, 2020
The White House looks to bring in credible experts for its Operation Warp Speed initiative to advance therapies and vaccines to combat the coronavirus pandemic.
The company announced that participants have enrolled in a Phase 1/2 clinical trial of its COVID-19 vaccine candidate, NVX‑CoV2373, a prefusion protein made using Novavax’s proprietary nanoparticle technology.
May 22, 2020
Funding from the US government could lead to 300 million coronavirus vaccine doses by October 2020.
May 21, 2020
The companies have formed a collaboration to develop a novel human recombinant protein as a therapeutic candidate against COVID-19.
CanSinoBIO will license-in Precision NanoSystems' proprietary RNA vaccine platform technology while the latter leads the development of the RNA vaccine formulation.
The Trump Administration has awarded a hefty contract to a new pharmaceutical manufacturing consortium to produce in the United States all components of certain critical medicines needed to combat COVID-19.
May 20, 2020
US manufacturers focus on preparing capacity while vaccines and treatments for COVID-19 are being developed and tested.